No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $6 Price Target
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450's Broad Market Potential
Express News | AEON Biopharma Shares Are Trading Higher After the Company Announced a Resource Prioritization and Cost Reduction Plan
AEON Biopharma Shares Jump on Job Cuts, CFO Firing
By Dean Seal Shares of AEON Biopharma climbed after the company said it laid off more than half of its staff, including its chief financial officer, so as to extend its cash runway through the end of
AEON Biopharma: Cost-Reduction Actions to Include Efforts to Cut Additional Operating Costs, Expected to Be Substantially Completed by June 2024 >AEON
AEON Biopharma: Cost-Reduction Actions to Include Efforts to Cut Additional Operating Costs, Expected to Be Substantially Completed by June 2024 >AEON
AEON Biopharma Names Corporate Controller Jennifer Sy as Principal Acctg Officer >AEON
AEON Biopharma Names Corporate Controller Jennifer Sy as Principal Acctg Officer >AEON
No Data